A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy.

Cetuximab in combination with an irinotecan-containing regimen is a standard treatment in patients with KRAS wild-type (KRAS WT), metastatic colorectal cancer (mCRC). We investigated the addition of the oral MET inhibitor tivantinib to cetuximab + irinotecan (CETIRI) based on preclinical evidence that activation of the MET pathway may confer resistance to anti-EGFR therapy. Previously treated patients with KRAS WT advanced or mCRC were enrolled.

[Distal pancreatic resection with common hepatic artery en block].

One of the most frequent cause of inoperability of the pancreatic tumor is the vascular invasion of truncus coeliacus and common hepatic artery. In 1953 Appleby suggested the en block truncus coeliacus and distal pancreatic resection together with gastrectomy for the treatment of the locally disseminated gastric cancer. The method was later modified for the resection of pancreatic body and tail tumors (without gastrectomy) and in 1991 was named "the modified Appleby operation".

[Use of implanted intravascular catheters with subcutaneous "ports" in the treatment of surgical diseases].

Special implanted vascular catheters with subcutaneous "ports" were used in 120 patients for infusions into arteries, veins and abdominal cavity. The results demonstrate high efficacy of this method in the treatment of surgical and cancer patients.

[Laparoscopy and puncture biopsy in diagnosis of focal lesions of the liver].

Based on the results of examination of 208 patients with different tumors of the liver it is concluded that in the majority of cases it is possible to avoid puncture biopsy of the liver and laparoscopy for diagnosis of focal lesion of the liver (FLL) before surgery because these invasive procedures don't improve efficacy of diagnosis. On the contrary it may lead to complications including implantation metastases (3.33%).